about
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trialTargeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionTumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimenESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes.ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoformImpact of centralization on aCGH-based genomic profiles for precision medicine in oncology.A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomasCyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.Exosome-based immunotherapy.Targeted therapies for ER+/HER2- metastatic breast cancer.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewThe potential of exosomes in immunotherapy.The potential of exosomes in immunotherapy of cancer.Dendritic cell derived-exosomes: biology and clinical implementations.The anticancer immune response: indispensable for therapeutic success?Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteersrCGH: a comprehensive array-based genomic profile platform for precision medicine.What can breast cancer molecular sub-classification add to conventional diagnostic tools?The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.Gene expression predictors in breast cancer: current status, limitations and perspectives.Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.P53 family: at the crossroads in cancer therapy.Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers.mTOR inhibitors in advanced breast cancer: ready for prime time?Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
P50
Q24801506-9A831705-3184-45F9-B1C0-1ABC1E979149Q27852282-9C4FC26A-47B4-49BD-A8C5-BA4DC78F0ABEQ27853377-40B81B77-F6AE-4242-90B1-1708D6689CC8Q28655705-AB4A6F83-17A6-4D6A-8DEB-A5A4C689694CQ29122940-4D4E41A7-05A9-4EA6-B49C-97F0F945BC11Q30317064-236AE23D-1D52-4004-829E-D5E402BEEC83Q30580553-CFCF0CE7-020F-452A-87EC-A07ECF245097Q33410791-A638B70B-2E77-414A-8A42-D7600070B330Q33421740-692285AC-3740-4E23-A77D-253C59C4FE0AQ33423263-F63D5FC6-0194-4A22-8DE8-51C7E06AEE19Q34344437-9470506F-0F8D-47A9-BAAC-CCEE5AF8CC38Q34564091-2ABEE683-1282-4D3E-A40E-1D47FFB20122Q34695223-68442209-22D7-440C-B8C7-F1632757E200Q34836082-607C2BCF-EAA8-4AA7-B800-7D32916111FDQ34987379-31832E0F-22CE-4E40-9FF9-3DBCC286CBA4Q35128506-00BC9F7D-228C-46FA-8715-22C4D0981FF1Q35208166-B8B230D9-23B7-4267-97C5-B27C4CDAAB37Q35583968-484D288B-DB15-4B89-8683-96EBBED03B5CQ35630835-E272A2E9-A887-4094-99E9-7EC607E9C0DBQ35658860-037238D0-578B-40D6-9AC6-DE8B37BA0719Q35904441-580A425D-9F46-41A6-80D7-C369660BDAB7Q36161201-BFDDC627-A328-4B12-90EC-FC0F93D0F5E8Q36199323-D13D1A96-55FE-4837-82AE-11E7D16BFA03Q36523645-CCC572AE-F229-4E5C-96C8-F0795FE99C6EQ36677608-9C98903E-D1B7-404B-8F07-F2E87F568A56Q36755179-309F396D-B407-4CF5-90A9-AD3FE37CDCB9Q36845431-77E7176A-836C-4DA8-9D3C-BBD70AC3E0D9Q36882019-7725EA1E-86BF-4CBF-B10A-89059E208474Q36990578-76271C7F-6095-4E43-AC26-0C5EB0DFE98FQ37314811-465F9FF9-5375-4669-AEFC-95159F3F002DQ37379394-BC2FFE39-6EC5-4871-B9CF-C7D07B75D0EDQ37597306-9C820557-66E6-4D6B-AE70-13442DE5F159Q37765470-73254FE9-A337-49E0-90DD-AE2672517292Q37777749-BC35F0EB-50B9-4DD6-B3E3-02229BE45733Q37799942-D440A9DB-0822-4A1F-88F5-BF1D89D296B2Q37811696-FBD6C94D-410C-421E-B4D4-DDF79D7E8F75Q38000790-4D8F4C2C-0362-4BE3-9E70-12DEB1D737E4Q38019720-0A5AE8DF-9C5A-46CF-BED5-D2150B9F2813Q38096134-EC55CF7A-4943-47B8-B38B-39C5F4241348Q38184616-92E775E1-301C-439F-B535-0AFF80B46A83
P50
description
Frans oncoloog
@nl
hulumtues
@sq
oncólogu francés
@ast
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Fabrice André
@ast
Fabrice André
@ca
Fabrice André
@en
Fabrice André
@es
Fabrice André
@fr
Fabrice André
@nl
Fabrice André
@sl
type
label
Fabrice André
@ast
Fabrice André
@ca
Fabrice André
@en
Fabrice André
@es
Fabrice André
@fr
Fabrice André
@nl
Fabrice André
@sl
prefLabel
Fabrice André
@ast
Fabrice André
@ca
Fabrice André
@en
Fabrice André
@es
Fabrice André
@fr
Fabrice André
@nl
Fabrice André
@sl
P214
P269
P4285
P106
P1412
P21
P214
P269
P27
P31
P4124
fabrice-andre_70679
P4285
P496
0000-0002-6272-6048
P569
1972-05-10T00:00:00Z
P735
P7859
viaf-305295004